A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
OHSU Knight Cancer Institute
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Jonsson Comprehensive Cancer Center
Medical College of Wisconsin
Pfizer
Accent Therapeutics
City of Hope Medical Center
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
Novartis
Novartis
Fox Chase Cancer Center
Case Comprehensive Cancer Center
Chongqing Precision Biotech Co., Ltd
Elicio Therapeutics
Affiliated Cancer Hospital of Shantou University Medical College
City of Hope Medical Center
City of Hope Medical Center
Medicine Invention Design, Inc
Columbia University